ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Istaroxime

Also written as “istaroxime”.

Its studies are mostly in Heart Failure · Shock, Cardiogenic, led by 5 companies.

Drug pageIstaroxime: every studyMany companies study it; this page follows only the 8 they lead. All 9 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jul 9, 20158 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Windtree Therapeuticsits history only31 open or runningphase 2since Jul 9, 2015Jul 9, 2015none ahead
Debiopharmits history only20 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead
Lee's Pharmaceuticalits history only10 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
Seismic Pharmaceuticals Operations11 open or runningphase 3since May 1, 2026May 1, 2026Dec 2028phase 3 · NCT07583446
sigma-tau i.f.r.its history only10 open or runningphase 2since Feb 5, 2008Feb 5, 2008none ahead

Also a collaborator on its studies: CVie Therapeutics, Momentum Research and MDS Pharma Services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Seismic Pharmaceuticals Operations only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 1, 2026First study: phase 3 study in Shock, CardiogenicFirst studyNCT07583446 · 600 planned · Armenia

Ahead

  1. Dec 2028Primary completion: phase 3 study in Shock, CardiogenicNCT07583446

TargetBeta

“Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator”ChEMBL 37, by rule

Studies

The one study Seismic Pharmaceuticals Operations leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07583446Shock, Cardiogenic · Armenia3RecruitingDec 2028600

How it is read

Names in the registry

  • “Istaroxime”, 13 entries
  • “istaroxime”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.